array:23 ["pii" => "S0300289623003800" "issn" => "03002896" "doi" => "10.1016/j.arbres.2023.11.012" "estado" => "S300" "fechaPublicacion" => "2024-01-01" "aid" => "3441" "copyright" => "SEPAR" "copyrightAnyo" => "2023" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Arch Bronconeumol. 2024;60:67-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:17 [ "pii" => "S0300289623003733" "issn" => "03002896" "doi" => "10.1016/j.arbres.2023.11.007" "estado" => "S300" "fechaPublicacion" => "2024-01-01" "aid" => "3436" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "err" "cita" => "Arch Bronconeumol. 2024;60:69" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:9 [ "idiomaDefecto" => true "cabecera" => "Erratum" "titulo" => "Erratum to “Iatrogenic Adrenal Insufficiency Following Post COVID-19 Organizing Pneumonia” [Archivos de Bronconeumologia 59 (2023) 63–65]" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "69" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Esther Palones, Elena Curto, Anna Pelegrí, Marina Arilla, Ingrid Solanes, Astrid Crespo-Lessmann" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Esther" "apellidos" => "Palones" ] 1 => array:2 [ "nombre" => "Elena" "apellidos" => "Curto" ] 2 => array:2 [ "nombre" => "Anna" "apellidos" => "Pelegrí" ] 3 => array:2 [ "nombre" => "Marina" "apellidos" => "Arilla" ] 4 => array:2 [ "nombre" => "Ingrid" "apellidos" => "Solanes" ] 5 => array:2 [ "nombre" => "Astrid" "apellidos" => "Crespo-Lessmann" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289623003733?idApp=UINPBA00003Z" "url" => "/03002896/0000006000000001/v3_202406051404/S0300289623003733/v3_202406051404/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0300289623003666" "issn" => "03002896" "doi" => "10.1016/j.arbres.2023.10.011" "estado" => "S300" "fechaPublicacion" => "2024-01-01" "aid" => "3429" "copyright" => "SEPAR" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Arch Bronconeumol. 2024;60:65-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "Letter to the Director" "titulo" => "Initial Treatment in COPD Patients. Do We Take into Account the Severity of the Exacerbation?" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "65" "paginaFinal" => "66" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1537 "Ancho" => 2508 "Tamanyo" => 184741 ] ] "descripcion" => array:1 [ "en" => "Proposal for initial pharmacological treatment. Low risk: Patients who present mild or moderate airflow obstruction, low degree of dyspnea (mMRC of 0–1) and ≤1 exacerbation that has not required admission (all criteria must be met). High risk: Patients who present severe or very severe airflow obstruction, a high degree of dyspnea (mMRC≥2) and/or at least ≥2 moderate exacerbations in the previous year or at least 1 that required hospital admission (at least 1 criterion must be met). Abbreviations: LAMA: long-acting muscarinic antagonist; LABA: long-acting β2-agonist; ICS: inhaled corticosteroid; Eo: eosinophils." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Juan Marco Figueira-Gonçalves, Javier de Miguel-Díez" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Juan Marco" "apellidos" => "Figueira-Gonçalves" ] 1 => array:2 [ "nombre" => "Javier" "apellidos" => "de Miguel-Díez" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289623003666?idApp=UINPBA00003Z" "url" => "/03002896/0000006000000001/v3_202406051404/S0300289623003666/v3_202406051404/en/main.assets" ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "Letter to the Director" "titulo" => "Reply to Figueroa-Gonçalves and de Miguel-Díez" "tieneTextoCompleto" => true "saludo" => "To the Director," "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "67" "paginaFinal" => "68" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Marc Miravitlles, Konstantinos Kostikas, Nikoletta Bizymi, Nikolaos Tzanakis" "autores" => array:4 [ 0 => array:4 [ "nombre" => "Marc" "apellidos" => "Miravitlles" "email" => array:1 [ 0 => "marcm@separ.es" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Konstantinos" "apellidos" => "Kostikas" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "Nikoletta" "apellidos" => "Bizymi" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] ] ] 3 => array:3 [ "nombre" => "Nikolaos" "apellidos" => "Tzanakis" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Pneumology Department, Hospital Universitari Vall d’Hebron, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Barcelona Hospital Campus, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Respiratory Medicine Department, University of Ioannina, Greece" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Department of Respiratory Medicine, University Hospital of Heraklion, Medical School, University of Crete, Heraklion, Greece" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "textoCompleto" => "We thank Figueroa-Gonçalves and de Miguel-Díez for their interest and comments about our manuscript on a new treatment algorithm for COPD.<a class="elsevierStyleCrossRef" href="#bib0030">1</a> In our proposal, we restricted the indication of triple therapy with LAMA/LABA/ICS as initial therapy for exacerbators with >300 blood eosinophils (BEC), while they suggest that in case of severe exacerbations triple therapy should be recommended at lower levels of BEC (i.e. >100).<a class="elsevierStyleCrossRef" href="#bib0035">2</a> They base their recommendation in the fact that severe exacerbations have a high impact on the natural history of COPD, are followed by a high frequency of readmissions, and that it is not uncommon for admitted patients with COPD to be treatment naïve.<a class="elsevierStyleCrossRef" href="#bib0035">2</a> There is no discussion about this, but there is currently no concrete evidence that triple therapy will be more effective than dual bronchodilation at discharge in naïve patients with 100–300 eosinophils, as suggested by the authors.To further support their recommendation, Figueroa-Gonçalves and de Miguel-Díez indicate that a post hoc analysis of the IMPACT study demonstrates that the initiation of triple therapy after a severe COPD exacerbation provides a greater benefit in terms of the development of future exacerbations than LAMA/LABA in patients with a level of BEC >100. However, it is of note that patients in IMPACT were by no means treatment naïve; on the contrary, up to 40% were already on triple therapy at screening (therefore, they do not “initiate” triple after admission) and a further 41% were on either LABA/ICS or LAMA/LABA.<a class="elsevierStyleCrossRef" href="#bib0040">3</a> Moreover, looking at the mortality results, there was no effect whatsoever of triple therapy in reduction of mortality in patients who were not previously on ICS, which are the closer to treatment naïve that we can find in IMPACT.<a class="elsevierStyleCrossRef" href="#bib0040">3</a> For these reasons, the IMPACT study results cannot be extrapolated to treatment naïve subjects with COPD and cannot be used to justify triple therapy in previously naïve COPD patients after a severe exacerbation in all cases with BEC >100. We do not dispute the indication of triple therapy in discharged patients with BEC >300, since enough evidence exists about the great efficacy of ICS in this population, but naïve patients with BEC between 100 and 300 should try LABA/LAMA first and only escalate to triple in case of a new episode or frequent moderate exacerbations, as indicated in the GESEPOC guidelines.<a class="elsevierStyleCrossRef" href="#bib0045">4</a>Figueroa-Gonçalves y de Miguel-Díez also base their recommendation on data from the observational PRIMUS study, which observed lower mortality with the early initiation of triple after an admission compared with delayed initiation, but again patients in PRIMUS were not treatment naïve and the observational design may involve certain bias.<a class="elsevierStyleCrossRef" href="#bib0035">2</a> There are observational studies suggesting the opposite, for example, Jo et al.<a class="elsevierStyleCrossRef" href="#bib0050">5</a> observed that patients who discontinued their ICS after being discharged from an exacerbation of COPD had a significant reduction of 35% of the risk of re-hospitalisation or death compared with those who continued using their ICS. Therefore, we need to be very cautious with the recommendation to use triple therapy, even in patients after a hospital admission, because benefits do not always outweigh the risks, particularly in previously naïve patients with less than 300 BEC.Conflict of InterestsMarc Miravitlles has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Menarini, Kamada, Takeda, Zambon, CSL Behring, Specialty Therapeutics, Janssen, Grifols and Novartis, consulting fees from AstraZeneca, Atriva Therapeutics, Boehringer Ingelheim, BEAM Therapeutics, Chiesi, GlaxoSmithKline, CSL Behring, Inhibrx, Menarini, Mereo Biopharma, Spin Therapeutics, Specialty Therapeutics, ONO Pharma, Palobiofarma SL, Takeda, Novartis, Novo Nordisk, Sanofi, Zambon, Zentiva and Grifols and research grants from Grifols.Konstantinos Kostikas has received honoraria for presentations and/or consultancy fees from Alector Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, ELPEN, GILEAD, GSK, Menarini, Novartis, Pfizer, Sanofi, Specialty Therapeutics, WebMD; his department has received funding and/or grants from AstraZeneca, Boehringer Ingelheim, Chiesi, Innovis, ELPEN, GSK, Menarini, Novartis and NuvoAir; he is a member of the GOLD Assembly.Nikoletta Bizymi has no conflicts of interest related to this paper.Nikolaos Tzanakis has received speaker and/or consultancy fees from AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, ELPEN, GILEAD, GSK, Innovis, Menarini, Novartis, Pfizer, Sanofi, Specialty Therapeutics, Help and has received research grants from AstraZeneca, Boehringer Ingelheim, Chiesi, Innovis, GSK, Menarini, and Novartis." "textoCompletoSecciones" => array:1 [ "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Conflict of Interests" ] 1 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0030" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A novel figure and algorithm for the gold ABE classification" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "M. Miravitlles" 1 => "K. Kostikas" 2 => "N. Bizymi" 3 => "N. Tzanakis" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.arbres.2023.06.001" "Revista" => array:6 [ "tituloSerie" => "Arch Bronconeumol" "fecha" => "2023" "volumen" => "59" "paginaInicial" => "702" "paginaFinal" => "704" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/37355409" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0035" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Initial treatment in COPD patients. Do we take into account the severity of the exacerbation?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M. Figueroa-Gonçalves" 1 => "J. de Miguel-Díez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.arbres.2023.10.011" "Revista" => array:6 [ "tituloSerie" => "Arch Bronconeumol" "fecha" => "2024" "volumen" => "60" "paginaInicial" => "65" "paginaFinal" => "66" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/37985279" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0040" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D.A. Lipson" 1 => "C. Crim" 2 => "G.J. Criner" 3 => "N.C. Day" 4 => "M.T. Dransfield" 5 => "D.M.G. Halpin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.201911-2207OC" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2020" "volumen" => "201" "paginaInicial" => "1508" "paginaFinal" => "1516" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32162970" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0045" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Spanish COPD Guidelines (GesEPOC) 2021: updated pharmacological treatment of stable COPD" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Miravitlles" 1 => "M. Calle" 2 => "J. Molina" 3 => "P. Almagro" 4 => "J.T. Gómez" 5 => "J.A. Trigueros" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Arch Bronconeumol" "fecha" => "2022" "volumen" => "58" "paginaInicial" => "68" "paginaFinal" => "91" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0050" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Inhaled corticosteroid withdrawal may improve outcomes in elderly patients with COPD exacerbation: a nationwide database study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T. Jo" 1 => "H. Yasunaga" 2 => "Y. Yamauchi" 3 => "A. Mitani" 4 => "Y. Hiraishi" 5 => "W. Hasegawa" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "ERJ Open Res" "fecha" => "2020" "volumen" => "6" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/03002896/0000006000000001/v3_202406051404/S0300289623003800/v3_202406051404/en/main.assets" "Apartado" => array:4 [ "identificador" => "94562" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Letters to the Director" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/03002896/0000006000000001/v3_202406051404/S0300289623003800/v3_202406051404/en/main.pdf?idApp=UINPBA00003Z&text.app=https://archbronconeumol.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289623003800?idApp=UINPBA00003Z"]

Archivos de Bronconeumología

ISSN: 0300-2896

Archivos de Bronconeumologia is an international journal that publishes original studies whose content is based upon results of research initiatives dealing with several aspects of respiratory medicine including epidemiology, respiratory physiology, pathophysiology of respiratory diseases, clinical management, thoracic surgery, pediatric lung diseases, respiratory critical care, respiratory allergy and basic research. Other types of articles such as editorials, reviews, and different types of letters are also published in the journal. Additionally, the journal expresses the voice of the following scientific societies: the Spanish Respiratory Society of Pneumology and Thoracic Surgery (SEPAR; https://www.separ.es/), the Latin American Thoracic Society (ALAT; https://alatorax.org/), and the Iberian American Association of Thoracic Surgery (AIACT; http://www.aiatorax.com/).

It is a monthly journal in which all manuscripts are sent to peer-review and handled by the editor or an associate editor from the team and the final decision is made on the basis of the comments from the expert reviewers and the editors. The journal is published solely in English. All the published data is composed of novel manuscripts not previously published in any other journal and not being in consideration for publication in any other journal..

The journal is indexed at Science Citation Index Expanded, Medline/Pubmed, Embase and SCOPUS. Access to any published article is possible through the journal's web page as well as from Pubmed, ScienceDirect, and other international databases. Furthermore, the journal is also present in X, Facebook and Linkedin. Manuscripts can be submitted electronically using the following web site: https://www.editorialmanager.com/ARBR/.

Indexed in:

Current Contents/Clinical Medicine, JCR SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, SCOPUS, IBECS

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

Impact factor 2023

8.7

Citescore

CiteScore measures average citations received per document published.

Citescore 2023

3.5

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2023

0.464

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2023

0.482

View more metrics

Open Access Option

Journal Information

Previous article | Next article

Export reference

Download PDF

Purchase article

For the purchase of this article it is necessary to fill in the following form:

Name *

First surname *

Second surname

Email *

Address *

Number *

City *

Afganistan

Albania

Alemania

Andorra

Angola

Anguilla

Antartica

Antigua and barbuda

Antillas holandesas

Arabia saudita

Argelia

Argentina

Armenia

Aruba

Australia

Austria

Azerbaijan

Bahamas

Bahrain

Bangladesh

Barbados

Belarus

Belgica

Belice

Benin

Bermudas/antillas britanicas

Bhutan

Bolivia

Bosnia y herzegowina

Botswana

Brasil

Brunei darussalam

Bulgaria

Burkina faso

Burundi

Cabo verde

Camboya

Camerun

Canada

Chad

Chile

China

Chipre

Colombia

Comoros

Corea

Costa rica

Cote d´ivoire

Croacia

Cuba

Dinamarca

Djibouti

Dominica

East timor

Ecuador

Egipto

El salvador

Emiratos arabes unidos

Eritrea

Escocia

Eslovaquia

Eslovenia

España

Estados federados de micronesia

Estados unidos

Estonia

Etiopia

Fiji

Filipinas

Finlandia

Francia

Gabon

Gambia

Georgia

Ghana

Gibraltar

Grecia

Grenada

Groenlandia

Guadalupe

Guam

Guatemala

Guayana britanica

Guinea

Guinea ecuatorial

Guinea francesa

Guinea-bissau

Haiti

Holanda

Honduras

Hong kong

Hungria

India

Indonesia

Irak

Iran

Irlanda

Isla bouvet

Isla cocos (keeling)

Isla cook

Isla mauricio

Isla navidad

Isla norfolk

Islandia

Islas caiman

Islas falkland (malvinas)

Islas faroe

Islas georgia del sur y sandwich

Islas heard and mc donald

Islas marshall

Islas northern mariana

Islas salomon

Islas svalbard and jan mayen

Islas turks and caicos

Islas united states minor outlyi

Islas virgenes (britanicas)

Islas virgenes (u.s.a.)

Islas wallis and futuna

Israel

Italia

Jamaica

Japon

Jordania

Kazakhstan

Kenia

Kiribati

Kuwait

Kyrgyzstan

Lesoto

Letonia

Libano

Liberia

Libia arab jamahiriya

Liechtenstein

Lituania

Luxemburgo

Macao

Macedonia

Madagascar

Malasia

Malawi

Maldives

Mali

Malta

Marruecos

Martinica

Mauritania

Mayotte

Mexico

Monaco

Mongolia

Monserrat

Morocco

Mozambique

Myanmar

Namibia

Nauru

Nepal

Nicaragua

Niger

Nigeria

Niue

Noruega

Nueva caledonia

Nueva zelanda

Oman

Pakistan

Palau

Panama

Papua new guinea

Paraguay

Peru

Pitcairn

Polinesia francesa

Polonia

Portugal

Posesiones gran bretaña

Posesiones u.s.a.

Puerto rico

Qatar

Reino unido

Republica checa

Republica de africa central

Republica de cabo verde

Republica de congo

Republica de corea

Republica de moldova

Republica democratica de laos

Republica democratica del congo

Republica dominicana

Reunion

Ruanda

Rumania

Rusia

Sahara occidental

Saint kitts and nevis

Samoa

Samoa americana

San marino

San tomas y principe

San vincent and the grenadines

Santa lucia

Senegal

Serbia

Seychelles

Sierra leona

Singapur

Siria

Somalia

Sri lanka

St. helena

St. pierre and miquelon

Sudafrica

Sudan

Suecia

Suiza

Surinam

Swaziland

Tailandia

Taiwan republica de china

Tajikistan

Tanzania

Territorio de indias britanicas

Togo

Tokelau

Tonga

Trinidad and tobago

Tunisia

Turkmenistan

Turquia

Tuvalu

Ucrania

Uganda

Uruguay

Uzbekistan

Vanuatu

Vaticano

Venezuela

Vietnam

Yemen

Yugoslavia

Zambia

Zimbawe

Lebanon

Paises bajos

A coruña

Alava

Albacete

Alicante

Almeria

Asturias

Avila

Badajoz

Balears

Barcelona

Bizkaia

Burgos

Caceres

Cadiz

Cantabria

Castellon

Ceuta

Ciudad real

Cordoba

Cuenca

Girona

Granada

Guadalajara

Guipuzcoa

Huelva

Huesca

Jaen

La rioja

Las palmas

Leon

Lleida

Lugo

Madrid

Malaga

Melilla

Murcia

Navarra

Ourense

Palencia

Pontevedra

Salamanca

Segovia

Sevilla

Soria

Tarragona

Tenerife

Teruel

Toledo

Valencia

Valladolid

Zamora

Zaragoza

-- Not applicable --

Código postal *

Phone *

NIF o número identificativo *

I accept to receive information about Elsevier's special products and promotions by email

I accept to receive information about products and special promotions from Elsevier partners by email

I have read and understand the Privacy Policy and Terms and conditions and agree to be bound by all of its terms.

* Required fields

In addition to temporary access to the article, it will be sent by email.

Customer Support

Phone

Calls from Spain

932 415 960

Calls from abroad

+34 932 415 960

Hours from 9 a.m. to 6 p.m. except the months of July and August, which will be from 9 am to 3 pm.

Publish in

Archivos de Bronconeumología

Free access articles

Effects of Posture on the Inspiratory and Expiratory...

10.1016/j.arbres.2024.09.011

Pulmonary Hamartoma With Rare Imaging...

10.1016/j.arbres.2024.09.015

Corrigendum to “Chronic respiratory diseases as a...

Arch Bronconeumol. 2024;60:539-40

Podcast

Respiratory Syncytial Virus Vaccination Recommendations for Adults Aged 60 Years and Older: The NeumoExperts Prevention Group Position Paper

Graphical abstract

Archivos de Bronconeumología is a member and subscribes the principles of, the Committee on Publication Ethics (COPE)
www.publicationethics.org.

Archivos de Bronconeumología follows the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals

Indexed in:

Follow us:

Subscribe:

Purchase article

Subscribe to our newsletter